Business
Investors in drugmaker Mesoblast sweat on crucial capital raising – Sydney Morning Herald
The stem cell giant says it needs cash from its existing partnerships to ‘continue as a going concern’.
The ability of the group to continue as a going concern and realise its assets and discharge its liabilities in the normal course of business are dependent on cash inflows from successfully completing the private placement, as well as from existing strategic and financing partnerships, the auditors report said.
Analysts at Bell Potter noted last month that Mesoblasts balance sheet could come under pressure in the 2022 financial year if there were any hiccups with agreements and payments from partners…
-
Noosa News19 hours agoWoman charged with murder over fire that killed mother, boys
-
Noosa News15 hours ago69yo man could see new charges over outback deaths
-
Business22 hours agoAmpol successfully issues $500 million subordinated notes
-
Noosa News11 hours agoState government changes definition of woman